ReviewBiologia futura2021
Pharmaceutical drug development: high drug prices and the hidden role of public funding.
Review in Biologia futura, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Pooled it
- The complex price setting and reimbursement of non-industrial advanced therapy medicinal products.Health economics review · 2026Article
- Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.Frontiers in pharmacology · 2026Article
- Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review.Applied health economics and health policy · 2026Article
- AI-powered IC50 prediction for p53 inhibitors drug-target interaction via hybrid graph neural networks.Journal of computer-aided molecular design · 2025Article
- How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases.Orphanet journal of rare diseases · 2025Article
- Children's drug research and development incentives and market pricing optimization based on medical imaging.Scientific reports · 2025Article
- Advancing Precision Medicine in Inflammatory Skin Disease.American journal of clinical dermatology · 2025Review
- Debates over orphan drug pricing: a meta-narrative literature review.Orphanet journal of rare diseases · 2025Review
- Can the Marketing Authorisation Holder system improve the ESG performance of pharmaceutical manufacturers?Frontiers in public health · 2025Article
- Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Association between 23 drugs and inflammatory bowel disease: a two-sample Mendelian randomization study.Frontiers in medicine · 2024Article
- Antisense oligonucleotides and their applications in rare neurological diseases.Frontiers in neuroscience · 2024Review
- Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.Cost effectiveness and resource allocation : C/E · 2022Article
- How to Improve Research Funding in Academia? Lessons From the COVID-19 Crisis.Frontiers in research metrics and analytics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2019, the record for the most expensive drug was broken at US$2.1 million per patient. The high costs of new drugs are justified by the pharmaceutical industry as the expense required for maintaining research and development (R&D) pipelines. However, this does not take into account that globally the public pays for between one to two-thirds of upfront R&D costs through taxpayers or charitable donations. Governments are effectively paying twice for medicines; first through R&D, and then paying the high prices upon approval. High drug prices distort research priorities, emphasising financial gains and not health gains. In this manuscript, issues surrounding the current patent-based drug development model, public funding of research and pharmaceutical lobbying will be addressed. Finally, innovations in drug development to improve public health needs and guaranteeing medication access to patients will be explored.
Indexed as
Identifiers
34554467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.